Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B
- PMID: 39841247
- PMCID: PMC11922970
- DOI: 10.1007/s00535-025-02211-5
Usefulness of serum HBV RNA levels for predicting antiviral response to entecavir treatment in patients with chronic hepatitis B
Abstract
Background: Hepatitis B virus (HBV) RNA is an important serum biomarker of hepatic covalently closed circular DNA (cccDNA) transcriptional activity; however, its clinical characteristics remain unclear. This study evaluated the clinical utility of HBV RNA levels in patients with chronic hepatitis B (CHB).
Methods: We studied 87 CHB patients with serum HBV DNA levels ≥ 5.0 log IU/mL who initiated entecavir (ETV) treatment between 2000 and 2018. Serum HBV RNA levels were measured at three-time points: before ETV treatment, at 12 weeks, and at 48 weeks after starting ETV treatment. Clinical markers associated with the antiviral effects of ETV treatment were analyzed.
Results: Serum HBV RNA levels decreased in both HBeAg-positive and -negative patients during the observation period. In HBeAg-positive patients, multivariable analysis showed that lower HBV RNA levels at 48 weeks of ETV treatment were independently associated with HBeAg seroconversion. Additionally, lower baseline HBV RNA levels significantly predicted virologic response in those patients. In contrast, among HBeAg-negative patients, lower HBV core-related antigen (HBcrAg) levels and the FIB-4 index were independently associated with virologic response. In HBeAg-positive patients, those with higher baseline HBV RNA levels showed a more significant reduction in hepatitis B surface antigen levels.
Conclusion: Serum HBV RNA levels predicted HBeAg seroconversion and early HBV DNA reduction in HBeAg-positive patients, while HBcrAg was significantly associated with virologic response in HBeAg-negative patients. These findings highlight the different predictive roles of HBV RNA and HBcrAg based on HBeAg status, which may provide individualized treatment strategies.
Keywords: Entecavir; HBV DNA; HBV RNA; HBeAg seroconversion; HBsAg.
© 2025. The Author(s).
Conflict of interest statement
Declarations. Conflict of interest: All authors declare that they have no affiliations with or involvement in any organization with any financial or non-financial interests in the subject matter or materials discussed in this manuscript. Ethical approval and informed consent: All the participants provided written informed consent. This study was approved by the Ethics Committee of Hiroshima University, Hiroshima, Japan (Approved ID: E2016-0704). This study was conducted in accordance with the principles of the Declaration of Helsinki. All authors declare that they have no affiliations with or involvement in any organization with any financial or non-financial interests in the subject matter or materials discussed in this manuscript.
Figures



Similar articles
-
Correlation of HBcrAg with Intrahepatic Hepatitis B Virus Total DNA and Covalently Closed Circular DNA in HBeAg-Positive Chronic Hepatitis B Patients.J Clin Microbiol. 2019 Jan 2;57(1):e01303-18. doi: 10.1128/JCM.01303-18. Print 2019 Jan. J Clin Microbiol. 2019. PMID: 30355757 Free PMC article.
-
Serum hepatitis B virus RNA is a predictor of HBeAg seroconversion and virological response with entecavir treatment in chronic hepatitis B patients.World J Gastroenterol. 2019 Feb 14;25(6):719-728. doi: 10.3748/wjg.v25.i6.719. World J Gastroenterol. 2019. PMID: 30783375 Free PMC article.
-
[Clinical effect of entecavir versus tenofovir in treatment of HBeAg-positive chronic hepatitis B patients with a high viral load: a comparative analysis].Zhonghua Gan Zang Bing Za Zhi. 2017 Oct 20;25(10):721-725. doi: 10.3760/cma.j.issn.1007-3418.2017.10.001. Zhonghua Gan Zang Bing Za Zhi. 2017. PMID: 29108198 Chinese.
-
A critique and systematic review of the clinical utility of hepatitis B core-related antigen.J Hepatol. 2023 Apr;78(4):731-741. doi: 10.1016/j.jhep.2022.12.017. Epub 2022 Dec 28. J Hepatol. 2023. PMID: 36586590
-
Hepatitis B core-related antigen as a promising serological marker for monitoring hepatitis B virus cure.World J Hepatol. 2025 Jan 27;17(1):98658. doi: 10.4254/wjh.v17.i1.98658. World J Hepatol. 2025. PMID: 39871916 Free PMC article. Review.
References
-
- World Health Organization. Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections. Available online: https://www.who.int/publications/i/item/9789240027077 Accessed on 13 May 2024
-
- Iloeje UH, Yang HI, Chen CJ. Natural history of chronic hepatitis B: what exactly has REVEAL revealed? Liver Int. 2012;32(9):1333–41. 10.1111/j.1478-3231.2012.02805.x. (Epub 2012 Apr 17 PMID: 22510145). - PubMed
-
- Brechot C, Gozuacik D, Murakami Y, et al. Molecular bases for the development of hepatitis B virus (HBV)-related hepatocellular carcinoma (HCC). Semin Cancer Biol. 2000;10:211–31. - PubMed
-
- Nagaya T, Nakamura T, Tokino T, et al. The mode of hepatitis B virus DNA integration in chromosomes of human hepatocellular carcinoma. Genes Dev. 1987;1:773–82. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources